^
    Back
    Association details:
    Biomarker:PIK3CA mutation + TERT promoter mutation
    Cancer:Liposarcoma
    Drug:Yondelis (trabectedin) (Alkylating agent, DNA inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    Clinical implications of recurring mutations in myxoid liposarcoma (MLS).

    Published date:
    05/25/2023
    Excerpt:
    For T, PIK3CAm/TERTm (n = 3) showed a trend for lower PFS (1.3 mo) in contrast to other groups (23 mo).
    DOI:
    10.1200/JCO.2023.41.16_suppl.11577